Cantor Fitzgerald Comments on Prothena FY2026 Earnings

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Prothena in a report released on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan anticipates that the biotechnology company will post earnings of ($3.66) per share for the year. Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share.

PRTA has been the topic of a number of other research reports. Oppenheimer downgraded Prothena from an "outperform" rating to a "market perform" rating in a research report on Tuesday, May 27th. Wall Street Zen raised shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. HC Wainwright cut their target price on Prothena from $30.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 27th. Jefferies Financial Group cut Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target on the stock. in a research note on Tuesday, May 27th. Finally, JMP Securities dropped their price objective on Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research note on Tuesday, May 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Prothena presently has a consensus rating of "Hold" and a consensus target price of $31.50.

Prothena Stock Up 0.2%

NASDAQ:PRTA traded up $0.01 on Tuesday, hitting $5.08. The stock had a trading volume of 806,357 shares, compared to its average volume of 719,712. The company has a fifty day moving average price of $7.50 and a two-hundred day moving average price of $11.80. Prothena has a 1-year low of $4.32 and a 1-year high of $25.42. The stock has a market cap of $273.44 million, a price-to-earnings ratio of -2.21 and a beta of -0.08.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The firm had revenue of $2.83 million for the quarter, compared to analyst estimates of $8.18 million. During the same period in the previous year, the firm posted ($1.34) EPS. The company's revenue was up 5500.0% compared to the same quarter last year.

Institutional Trading of Prothena

Several hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its holdings in Prothena by 22.8% during the 4th quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock worth $71,063,000 after purchasing an additional 952,088 shares during the period. Boxer Capital Management LLC purchased a new stake in shares of Prothena during the fourth quarter worth approximately $9,556,000. Federated Hermes Inc. raised its holdings in Prothena by 84.3% in the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock valued at $10,335,000 after acquiring an additional 341,274 shares in the last quarter. Finepoint Capital LP lifted its stake in Prothena by 51.6% in the fourth quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company's stock worth $9,100,000 after acquiring an additional 223,600 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Prothena by 93.7% during the 4th quarter. JPMorgan Chase & Co. now owns 387,350 shares of the biotechnology company's stock worth $5,365,000 after acquiring an additional 187,364 shares in the last quarter. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.